KINAXO Enters Agreement with Bristol-Myers Squibb Company
KINAXO Biotechnologies GmbH announced that Bristol-Myers Squibb Company has chosen KINAXO to support several of its drug discovery programs. Under the terms of the agreement, KINAXO will apply its chemical proteomics technologies to deconvolute molecular targets of compounds currently undergoing discovery research at Bristol-Myers Squibb to enable more informed decisions at various stages of the drug discovery process, such as selecting the right compound for clinical development.
Dr Jutta Fritz, Head of Business Development at KINAXO commented: “We are very pleased to collaborate with Bristol-Myers Squibb, one of the most prestigious pharmaceutical companies in the world. We are looking forward to building a productive partnership with Bristol-Myers Squibb, and consider this move to be a major milestone in expanding our business in the United States.”
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.